• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » TMS: Deeper is not Better

TMS: Deeper is not Better

January 13, 2020
Edmund S. Higgins, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Edmund S. Higgins, MD. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Filipcic I et al, J Psychiatr Res 2019;114:113–119


TYPE OF STUDY: Randomized single-blind controlled trial


Seven transcranial magnetic stimulation (TMS) devices are FDA approved for depression, but only one—the Brainsway—is distinctly different from the others. Brainsway uses a patented H1 coil that penetrates deeper into the cortex than the standard figure-8 coil. Brainsway’s marketing materials suggest that deeper is better, but the two versions of TMS have never been compared head to head—until now.


In this non-industry-sponsored study, 228 patients with moderate major depression were randomized to 1 of 3 arms over 4 weeks: TMS with the H1 coil, TMS with the figure-8 coil, or 2 visits of standard psychopharmacology. All patients were taking an antidepressant and stayed on that medication during the trial. The evaluators were blinded, but the patients knew which treatment they were getting. The primary outcome was remission on the 17-item Hamilton Rating Scale for Depression (HAMD-17). The study was funded by a public psychiatric hospital in Croatia, which is where the treatments were conducted.


The H1 coil and figure-8 coil were not statistically different on the primary outcome of remission, although both were superior to the standard psychopharmacology group. On secondary measures, the H1 coil had a greater response rate on the HAMD-17 than the figure-8 coil, but there were no differences in the total change on the HAMD-17 on quality-of-life measures. Likewise, safety and tolerability were equal for both devices.


These mixed results are similar to a recent meta-analysis that looked at outcomes in 19 studies of the 2 coils. The H1 coil led to greater reductions in depression severity, but the figure-8 coil had a slight advantage in remission rates (Gellersen HM and Kedzoir KK, BMC Psych 2019;19(1):139).


TCPR’s TAKE
Both types of TMS work, and deeper stimulation with the H1 coil does not work any better than earlier figure-8 coils.

General Psychiatry
KEYWORDS depression depressive_disorder pharmaceutical_industry research-update rtms tms transcranial-magnetic-stimulation treatment-resistant-depression
Edmund S. Higgins, MD.

A Review of Sexual Citizens

More from this author
www.thecarlatreport.com
Issue Date: January 13, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Esketamine, TCPR, January 2020
How to Treat Tardive Dyskinesia
Getting Uncomfortable with Esketamine
Antipsychotic Maintenance: How Long is Enough?
TMS: Deeper is not Better
In Brief: Antipsychotic Update
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.